{
    "id": 753,
    "fullName": "KIT over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "KIT over exp indicates an over expression of the KIT protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 3815,
        "geneSymbol": "KIT",
        "terms": [
            "KIT",
            "C-Kit",
            "CD117",
            "MASTC",
            "PBT",
            "SCFR"
        ]
    },
    "variant": "over exp",
    "createDate": "06/18/2014",
    "updateDate": "07/31/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 673,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Gleevec (imatinib) in conjunction with third-line chemotherapy resulted in a complete response in a patient with stage IV chemoresistant pure seminoma with KIT overexpression (PMID: 18751412).",
            "molecularProfile": {
                "id": 852,
                "profileName": "KIT over exp"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4440,
                "name": "seminoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 391,
                    "pubMedId": 18751412,
                    "title": "Complete response after imatinib mesylate administration in a patient with chemoresistant stage IV seminoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18751412"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13793,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Derazantinib (ARQ 087) inhibited growth of transformed cells overexpressing Kit in culture (PMID: 27627808).",
            "molecularProfile": {
                "id": 852,
                "profileName": "KIT over exp"
            },
            "therapy": {
                "id": 2900,
                "therapyName": "Derazantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11276,
                    "pubMedId": 27627808,
                    "title": "Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27627808"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6748,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case report, a patient with metastatic thymic carcinoma harboring KIT V560del with KIT over expression initially demonstrated stable disease and reduction in metastatic lesions following treatment with Gleevec (imatinib), but progressed after 6 months (PMID: 15201427).",
            "molecularProfile": {
                "id": 23682,
                "profileName": "KIT V560del KIT over exp"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3284,
                "name": "thymic carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5814,
                    "pubMedId": 15201427,
                    "title": "Thymic carcinoma with overexpression of mutated KIT and the response to imatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15201427"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 852,
            "profileName": "KIT over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23682,
            "profileName": "KIT V560del KIT over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}